Copyright Reports & Markets. All rights reserved.

Global Human Rabies Immunoglobulin (IM) Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Human Rabies Immunoglobulin (IM) Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 ERIG
    • 1.3.3 HRIG
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Human Rabies Immunoglobulin (IM) Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Category II Exposure
    • 1.4.3 Category III Exposure
  • 1.5 Global Human Rabies Immunoglobulin (IM) Market Size & Forecast
    • 1.5.1 Global Human Rabies Immunoglobulin (IM) Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global Human Rabies Immunoglobulin (IM) Sales Quantity (2020-2031)
    • 1.5.3 Global Human Rabies Immunoglobulin (IM) Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 CSL Behring
    • 2.1.1 CSL Behring Details
    • 2.1.2 CSL Behring Major Business
    • 2.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Product and Services
    • 2.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 CSL Behring Recent Developments/Updates
  • 2.2 Grifols
    • 2.2.1 Grifols Details
    • 2.2.2 Grifols Major Business
    • 2.2.3 Grifols Human Rabies Immunoglobulin (IM) Product and Services
    • 2.2.4 Grifols Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Grifols Recent Developments/Updates
  • 2.3 Sanofi
    • 2.3.1 Sanofi Details
    • 2.3.2 Sanofi Major Business
    • 2.3.3 Sanofi Human Rabies Immunoglobulin (IM) Product and Services
    • 2.3.4 Sanofi Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Sanofi Recent Developments/Updates
  • 2.4 Sichuan Yuanda Shuyang
    • 2.4.1 Sichuan Yuanda Shuyang Details
    • 2.4.2 Sichuan Yuanda Shuyang Major Business
    • 2.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product and Services
    • 2.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Sichuan Yuanda Shuyang Recent Developments/Updates
  • 2.5 Tiantan Bio
    • 2.5.1 Tiantan Bio Details
    • 2.5.2 Tiantan Bio Major Business
    • 2.5.3 Tiantan Bio Human Rabies Immunoglobulin (IM) Product and Services
    • 2.5.4 Tiantan Bio Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Tiantan Bio Recent Developments/Updates
  • 2.6 Kamada
    • 2.6.1 Kamada Details
    • 2.6.2 Kamada Major Business
    • 2.6.3 Kamada Human Rabies Immunoglobulin (IM) Product and Services
    • 2.6.4 Kamada Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Kamada Recent Developments/Updates
  • 2.7 CBPO
    • 2.7.1 CBPO Details
    • 2.7.2 CBPO Major Business
    • 2.7.3 CBPO Human Rabies Immunoglobulin (IM) Product and Services
    • 2.7.4 CBPO Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 CBPO Recent Developments/Updates
  • 2.8 Shuanglin Bio
    • 2.8.1 Shuanglin Bio Details
    • 2.8.2 Shuanglin Bio Major Business
    • 2.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product and Services
    • 2.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Shuanglin Bio Recent Developments/Updates
  • 2.9 Weiguang Bio
    • 2.9.1 Weiguang Bio Details
    • 2.9.2 Weiguang Bio Major Business
    • 2.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Product and Services
    • 2.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 Weiguang Bio Recent Developments/Updates
  • 2.10 Shanghai RAAS
    • 2.10.1 Shanghai RAAS Details
    • 2.10.2 Shanghai RAAS Major Business
    • 2.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product and Services
    • 2.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 Shanghai RAAS Recent Developments/Updates
  • 2.11 Bharat Serum
    • 2.11.1 Bharat Serum Details
    • 2.11.2 Bharat Serum Major Business
    • 2.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Product and Services
    • 2.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 Bharat Serum Recent Developments/Updates
  • 2.12 VINS
    • 2.12.1 VINS Details
    • 2.12.2 VINS Major Business
    • 2.12.3 VINS Human Rabies Immunoglobulin (IM) Product and Services
    • 2.12.4 VINS Human Rabies Immunoglobulin (IM) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.12.5 VINS Recent Developments/Updates

3 Competitive Environment: Human Rabies Immunoglobulin (IM) by Manufacturer

  • 3.1 Global Human Rabies Immunoglobulin (IM) Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Manufacturer (2020-2025)
  • 3.3 Global Human Rabies Immunoglobulin (IM) Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of Human Rabies Immunoglobulin (IM) by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 Human Rabies Immunoglobulin (IM) Manufacturer Market Share in 2024
    • 3.4.3 Top 6 Human Rabies Immunoglobulin (IM) Manufacturer Market Share in 2024
  • 3.5 Human Rabies Immunoglobulin (IM) Market: Overall Company Footprint Analysis
    • 3.5.1 Human Rabies Immunoglobulin (IM) Market: Region Footprint
    • 3.5.2 Human Rabies Immunoglobulin (IM) Market: Company Product Type Footprint
    • 3.5.3 Human Rabies Immunoglobulin (IM) Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Human Rabies Immunoglobulin (IM) Market Size by Region
    • 4.1.1 Global Human Rabies Immunoglobulin (IM) Sales Quantity by Region (2020-2031)
    • 4.1.2 Global Human Rabies Immunoglobulin (IM) Consumption Value by Region (2020-2031)
    • 4.1.3 Global Human Rabies Immunoglobulin (IM) Average Price by Region (2020-2031)
  • 4.2 North America Human Rabies Immunoglobulin (IM) Consumption Value (2020-2031)
  • 4.3 Europe Human Rabies Immunoglobulin (IM) Consumption Value (2020-2031)
  • 4.4 Asia-Pacific Human Rabies Immunoglobulin (IM) Consumption Value (2020-2031)
  • 4.5 South America Human Rabies Immunoglobulin (IM) Consumption Value (2020-2031)
  • 4.6 Middle East & Africa Human Rabies Immunoglobulin (IM) Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global Human Rabies Immunoglobulin (IM) Sales Quantity by Type (2020-2031)
  • 5.2 Global Human Rabies Immunoglobulin (IM) Consumption Value by Type (2020-2031)
  • 5.3 Global Human Rabies Immunoglobulin (IM) Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global Human Rabies Immunoglobulin (IM) Sales Quantity by Application (2020-2031)
  • 6.2 Global Human Rabies Immunoglobulin (IM) Consumption Value by Application (2020-2031)
  • 6.3 Global Human Rabies Immunoglobulin (IM) Average Price by Application (2020-2031)

7 North America

  • 7.1 North America Human Rabies Immunoglobulin (IM) Sales Quantity by Type (2020-2031)
  • 7.2 North America Human Rabies Immunoglobulin (IM) Sales Quantity by Application (2020-2031)
  • 7.3 North America Human Rabies Immunoglobulin (IM) Market Size by Country
    • 7.3.1 North America Human Rabies Immunoglobulin (IM) Sales Quantity by Country (2020-2031)
    • 7.3.2 North America Human Rabies Immunoglobulin (IM) Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe Human Rabies Immunoglobulin (IM) Sales Quantity by Type (2020-2031)
  • 8.2 Europe Human Rabies Immunoglobulin (IM) Sales Quantity by Application (2020-2031)
  • 8.3 Europe Human Rabies Immunoglobulin (IM) Market Size by Country
    • 8.3.1 Europe Human Rabies Immunoglobulin (IM) Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe Human Rabies Immunoglobulin (IM) Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific Human Rabies Immunoglobulin (IM) Market Size by Region
    • 9.3.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America Human Rabies Immunoglobulin (IM) Sales Quantity by Type (2020-2031)
  • 10.2 South America Human Rabies Immunoglobulin (IM) Sales Quantity by Application (2020-2031)
  • 10.3 South America Human Rabies Immunoglobulin (IM) Market Size by Country
    • 10.3.1 South America Human Rabies Immunoglobulin (IM) Sales Quantity by Country (2020-2031)
    • 10.3.2 South America Human Rabies Immunoglobulin (IM) Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa Human Rabies Immunoglobulin (IM) Market Size by Country
    • 11.3.1 Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa Human Rabies Immunoglobulin (IM) Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 Human Rabies Immunoglobulin (IM) Market Drivers
  • 12.2 Human Rabies Immunoglobulin (IM) Market Restraints
  • 12.3 Human Rabies Immunoglobulin (IM) Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Human Rabies Immunoglobulin (IM) and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Human Rabies Immunoglobulin (IM)
  • 13.3 Human Rabies Immunoglobulin (IM) Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Human Rabies Immunoglobulin (IM) Typical Distributors
  • 14.3 Human Rabies Immunoglobulin (IM) Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Human Rabies Immunoglobulin (IM) market size was valued at US$ 336 million in 2024 and is forecast to a readjusted size of USD 417 million by 2031 with a CAGR of 3.2% during review period.
    Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization. In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)
    The rising incidence of rabies, especially in developing countries, is a key driver of the human rabies immunoglobulin market. Rabies remains a significant public health concern, particularly in regions where animal vaccination programs are insufficient. Post-exposure prophylaxis (PEP), which includes human rabies immunoglobulin, is critical for preventing the virus after a bite from a rabid animal. Increasing awareness of rabies prevention, government initiatives, and partnerships with international health organizations have boosted demand for human rabies immunoglobulin in both rural and urban areas.
    A major challenge in the human rabies immunoglobulin market is its limited availability and high cost, particularly in low- and middle-income countries where rabies is most prevalent. The production of immunoglobulins requires advanced technology and biological materials, making it costly and sometimes scarce in regions with insufficient healthcare infrastructure. Additionally, the need for timely administration after exposure poses logistical difficulties, especially in remote areas, where access to healthcare facilities may be delayed, potentially limiting the effectiveness of the treatment.
    Asia-Pacific is expected to experience the highest growth in the market during the forecast period.
    This report is a detailed and comprehensive analysis for global Human Rabies Immunoglobulin (IM) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Human Rabies Immunoglobulin (IM) market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Human Rabies Immunoglobulin (IM) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Human Rabies Immunoglobulin (IM) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Human Rabies Immunoglobulin (IM) market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Human Rabies Immunoglobulin (IM)
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Human Rabies Immunoglobulin (IM) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL Behring, Grifols, Sanofi, Sichuan Yuanda Shuyang, Tiantan Bio, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Human Rabies Immunoglobulin (IM) market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    ERIG
    HRIG
    Market segment by Application
    Category II Exposure
    Category III Exposure
    Major players covered
    CSL Behring
    Grifols
    Sanofi
    Sichuan Yuanda Shuyang
    Tiantan Bio
    Kamada
    CBPO
    Shuanglin Bio
    Weiguang Bio
    Shanghai RAAS
    Bharat Serum
    VINS
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Human Rabies Immunoglobulin (IM) product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Human Rabies Immunoglobulin (IM), with price, sales quantity, revenue, and global market share of Human Rabies Immunoglobulin (IM) from 2020 to 2025.
    Chapter 3, the Human Rabies Immunoglobulin (IM) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Human Rabies Immunoglobulin (IM) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Human Rabies Immunoglobulin (IM) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Human Rabies Immunoglobulin (IM).
    Chapter 14 and 15, to describe Human Rabies Immunoglobulin (IM) sales channel, distributors, customers, research findings and conclusion.

    Buy now